The End of Emergency: PEMGARDA's Race for FDA Approval Begins

NEW HAVEN, Conn. – July 06, 2026 – The era of emergency measures for the COVID-19 pandemic is officially drawing to a close, but for biopharmaceutical firm Invivyd and the vulnerable patients it serves, a new and urgent clock has just started ticking. Following a declaration by the U.S. Department of Health and Human Services (HHS) to terminate the pandemic-era Emergency Use Authorization (EUA) framework, Invivyd has received a 12-month notice for its preventative COVID-19 antibody, PEMGARDA®. The authorization is now set to expire on June 29, 2027, forcing the company into a high-stakes race to secure a full Biologics License Application (BLA) from the FDA. The outcome will not only determine the future of Invivyd's flagship product but will also decide if a critical line of defense remains available for thousands of immunocompromised Americans.

A Regulatory Cliff and Procedural Fog

The termination of the EUA is a formal, system-wide shift, moving COVID-19 therapeutics from an emergency footing to the standard, more rigorous regulatory pathways. HHS has provided a 12-month transition period for drugs and biologics, a window deemed sufficient for companies to either secure full approval or wind down distribution. However, the path from an EUA to a BLA is fraught with complexity, and for Invivyd, the journey is clouded by what its leadership calls "procedural uncertainty."

According to the Federal Food, Drug, and Cosmetic Act, HHS is obligated to provide sponsors of EUA products with written advice on potential obstacles to full approval and the specific actions needed to overcome them. This provision is designed to create a clear, orderly ramp off the emergency highway. Yet, Invivyd's leadership has publicly expressed frustration over the apparent lack of this specific guidance.

“The end of a formal emergency for COVID products is in many ways overdue,” stated Marc Elia, Chairman of Invivyd’s Board of Directors, in a press release. “We regret that procedural uncertainty has needlessly intruded into our work on behalf of vulnerable Americans, who may find these headlines worrying and confusing.”

This regulatory ambiguity creates significant business risk. Elia contrasted PEMGARDA's situation with that of COVID-19 vaccines, noting that his company's antibody has generated extensive randomized clinical data, yet faces a more uncertain path than vaccine boosters that have received full approval. The core of the issue is whether the FDA will accept the existing data package as sufficient for a BLA or demand new, time-consuming trials—a critical question that remains unanswered.

A Lifeline for the Medically Vulnerable

The regulatory debate in Washington has immediate, real-world consequences for one of the pandemic's most fragile populations. PEMGARDA is not a treatment for the general public; it is authorized as a pre-exposure prophylaxis (PrEP) for moderately to severely immunocompromised adults and adolescents. This includes organ transplant recipients, patients undergoing chemotherapy, and others with conditions that prevent their bodies from mounting an adequate response to vaccination. For them, PEMGARDA acts as a non-vaccine shield, providing passive immunity through lab-engineered antibodies.

"This isn't just another therapeutic choice; for many of my patients, it's the only choice that gives them the confidence to engage with the world," explained an infectious disease specialist at a major academic medical center, who spoke on the condition of anonymity. "The potential for a gap in protection between the EUA ending and a BLA being approved is a source of profound anxiety."

The value of this protection is supported by emerging real-world evidence. A study following 166 immunocompromised patients with blood cancers between March 2024 and July 2025 found that PEMGARDA was well-tolerated. Only 4.8% of patients experienced a breakthrough COVID-19 infection, and critically, none of those cases led to hospitalization, ICU admission, or death. These results underscore the tangible benefit of the drug in preventing severe outcomes and reducing the burden on the healthcare system, a key data point as Invivyd makes its case for permanent approval.

Building the Case for Full Approval

Invivyd's confidence in securing a BLA rests on a substantial foundation of clinical data. The lynchpin is the CANOPY pivotal trial, which provided compelling evidence of the antibody's efficacy. In a placebo-controlled cohort, pemivibart—the active component in PEMGARDA—demonstrated an impressive 84.1% relative risk reduction in symptomatic COVID-19 through six months. This level of protection is particularly noteworthy because it was achieved against contemporary, immune-evasive SARS-CoV-2 variants circulating in the U.S., a feat that distinguishes it from earlier antibody therapies.

While the efficacy data is strong, the safety profile includes a notable warning. Anaphylaxis, a severe allergic reaction, was observed in 0.6% of trial participants, prompting the FDA to include a boxed warning on the product's fact sheet. This is a standard risk-management measure for many biologics and will be a key point of evaluation in the BLA review process.

The drug's initial EUA was granted using an immunobridging approach, which leverages data from its parent antibody, adintrevimab, to speed up authorization. Transitioning to a full BLA will require the FDA to be fully convinced that the existing data, including the CANOPY trial and post-authorization monitoring, is robust enough on its own. A significant and ongoing challenge is the relentless evolution of the virus. PEMGARDA's authorization is contingent on its effectiveness against circulating strains, with the FDA stipulating it can only be used when variants with reduced susceptibility make up less than 90% of those in the nation. This dynamic battlefield means Invivyd must continuously prove its product's relevance, a significant R&D and logistical burden that will persist even if a BLA is granted.

A Test Case for Post-Pandemic Regulation

Beyond the fate of a single company or product, Invivyd's predicament serves as a crucial test case for the entire U.S. pharmaceutical and public health apparatus. The transition away from the EUA framework marks a pivotal moment, forcing a systemic reckoning with how innovations developed under emergency conditions will survive in a post-pandemic market. The process will set precedents for dozens of other diagnostics, therapies, and devices that were rushed into service to combat the virus.

The business implications are stark. For years, the EUA pathway provided a lower-cost, faster route to market, incentivizing rapid innovation. The return to the standard BLA process, which is significantly more expensive and time-consuming, fundamentally changes the economic calculus for companies in the infectious disease space. Investors and executives will be watching the FDA’s handling of PEMGARDA’s application closely as a bellwether for the agency’s future posture.

The government's tiered approach—granting a 12-month transition for drugs but only 180 days for medical devices—reflects a calculated policy decision about the time needed to compile data and navigate regulatory channels. For Invivyd, that 12-month window is now a runway. The company's ability to successfully navigate the dialogue with the FDA and submit a compelling BLA will be a defining moment for its future and a powerful signal about the regulatory landscape for medical innovation in a world learning to live with COVID-19.